ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative) - Asset Purchase Agreement [Member] - Katana Pharmaceuticals, Inc [Member] $ in Millions |
Dec. 22, 2020
USD ($)
|
|---|---|
| Asset Acquisition [Line Items] | |
| Consideration paid | $ 0.7 |
| Research and development costs | $ 0.7 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|